Mibefradil
Clinical data | |
---|---|
Trade names | Posicor |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a607007 |
Routes of administration | By mouth (tablets) |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 70% |
Protein binding | >99% |
Metabolism | Liver (CYP3A4) |
Elimination half-life | 17–25 hours |
Identifiers | |
| |
JSmol) | |
Melting point | 128 °C (262 °F) (dihydrochloride salt) |
| |
| |
(what is this?) (verify) |
Mibefradil (trade name Posicor) was a
angina pectoris. It is a nonselective calcium channel blocker. It was voluntary pulled from the market ten months after FDA approval, citing potential serious health hazards shown in post release studies.[1]
The mechanism of action of mibefradil is characterized by the selective blockade of transient, low-voltage-activated (T-type) calcium channels over long-lasting, high-voltage-activated (L-type) calcium channels,[1] which is probably responsible for many of its unique properties.[citation needed]
On June 8, 1998,
Roche announced the voluntary withdrawal of the drug from the market, one year after approval by the FDA, due to the potential for drug interactions, some of them deadly, which may occur when it is taken together with some other medications.[2]
Synthesis
References
- ^ PMID 7565636.
- ^ Stolberg, Sheryl Gay (1998-06-09). "Heart Drug Withdrawn as Evidence Shows It Could Be Lethal". The New York Times. Retrieved 2019-01-12.